Jpmorgan Chase & CO Aadi Bioscience, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AADI
# of Institutions
65Shares Held
12MCall Options Held
9.4KPut Options Held
2.5K-
Avoro Capital Advisors LLC New York, NY2.85MShares$5.58 Million0.06% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2MShares$3.92 Million2.42% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$3.62 Million2.91% of portfolio
-
Satter Management Co., L.P.1.63MShares$3.2 Million4.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA766KShares$1.5 Million0.0% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $41.2M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...